DPN

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

Retrieved on: 
Tuesday, January 16, 2024

Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.

Key Points: 
  • Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.
  • Mediforum, a leading biotechnology firm in Korea, stands as a global pioneer in biotechnology, dedicated to advancing biomedical sciences through innovative and ethical practices.
  • With a diverse portfolio ranging from anti-dementia medications to health functional foods, Mediforum is at the forefront of biomedical innovation.
  • Both the surviving corporations of Initial Merger and SPAC Merger will be direct wholly owned subsidiaries of PubCo.

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Retrieved on: 
Wednesday, December 13, 2023

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
  • The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.
  • VX-548 was generally well tolerated at all doses tested in the study.
  • Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548.

BREAKTHROUGH IN DIGITAL HEALTH: WITHINGS HEALTH SOLUTIONS LAUNCHES BODY PRO 2, REVOLUTIONIZING THE DETECTION OF EARLY DIABETES COMPLICATIONS WITH THE NEXT-GEN CELLULAR SCALE

Retrieved on: 
Tuesday, November 14, 2023

BOSTON, Nov. 14, 2023 /PRNewswire/ -- Today, on World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2, a revolutionary device redefining the nature and use of cellular-connected smart scales. Body Pro 2 is the result of years of research and development, consultation with hundreds of digital health partners and clinicians, and embodies Withings' vision that digital health needs to be a better experience for all stakeholders. It combines habit-forming user features with a pioneering modular approach to manage chronic conditions within one versatile device. Its core capabilities allow care teams to capture advanced health metrics such as weight and body composition while additional and optional health modules unlock the ability to track advanced and clinically validated biomarkers typically only available in a professional setting.  

Key Points: 
  • Prevention of type 2 diabetes and diabetes-related complications is the focus of the final year of the World Diabetes Day 2021-23 theme, Access to Diabetes Care.
  • Body Pro 2's first module is prescription-only (Rx) and aims to improve the way patients with diabetes are taken care of.
  • With this module care teams can monitor one of the biggest challenges in diabetes, diabetic foot health, which is often overlooked.
  • 1
    With Body Pro 2, Withings Health Solutions reinforces its value proposition to the digital health industry.

'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum

Retrieved on: 
Monday, November 6, 2023

The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.

Key Points: 
  • The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.
  • With Diabetes Mellitus Type 2 being the leading cause of PN, its increasing prevalence is closely linked to the rise in the number of diabetics.
  • B vitamin deficiency and polymedication are other high-risk factors along with diabetes, leading to peripheral nerve damage.
  • Patients should be educated about the importance of regular foot and DPN examinations, glycemic control, and adherence to prescribed medications.

P&G Health commemorates World Diabetes Day 2023 with innovative AI-based Experiential Campaign #KnowtheSigns

Retrieved on: 
Wednesday, November 1, 2023

SINGAPORE, Nov. 1, 2023 /PRNewswire/ -- Ahead of World Diabetes Day 2023, P&G Health, makers of Neurobion, continued awareness efforts with an innovative #KnowtheSigns campaign to help consumers and healthcare professionals understand the connection between Diabetes and Pre-Diabetes with Peripheral Neuropathy (PN) and Vitamin B Deficiency for timely detection, treatment, and improved quality of life.

Key Points: 
  • SINGAPORE, Nov. 1, 2023 /PRNewswire/ -- Ahead of World Diabetes Day 2023, P&G Health, makers of Neurobion, continued awareness efforts with an innovative #KnowtheSigns campaign to help consumers and healthcare professionals understand the connection between Diabetes and Pre-Diabetes with Peripheral Neuropathy (PN) and Vitamin B Deficiency for timely detection, treatment, and improved quality of life.
  • With Diabetes Mellitus being the leading cause1 of PN, the increasing prevalence of PN is closely linked to the rise in the number of diabetic patients.
  • Symptoms of PN include numbness, tingling, prickling, and burning sensations in the hands and feet.
  • B vitamin deficiency and aging are other high-risk factors along with diabetes, leading to peripheral nerve damage.

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

Retrieved on: 
Tuesday, October 24, 2023

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

Key Points: 
  • DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
  • The Series B was led by new institutional investor, Double Point Ventures, and includes continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others.
  • These products prioritize the patient experience by addressing the root cause of both diseases with excellent efficacy, safety, and tolerability.
  • Phase 2b open label clinical trial in 10 subjects with DPN (Dermatosis Papulosa Nigra) treated with SM-020 gel 1% twice daily for 28 days.

University of Phoenix College of Doctoral Studies’ Scholars Present at 2023 International Leadership Association 25th Global Conference

Retrieved on: 
Friday, September 29, 2023

Leadership, faculty, students, and fellows-in-residence with the University of Phoenix College of Doctoral Studies and research centers join the proceedings of the International Leadership Association’s (ILA) 25th Global Conference, “Cultivating Leadership for a Thriving Future,” taking place online, October 3-4, 2023, and in person October 12-15 in Vancouver, Canada.

Key Points: 
  • Leadership, faculty, students, and fellows-in-residence with the University of Phoenix College of Doctoral Studies and research centers join the proceedings of the International Leadership Association’s (ILA) 25th Global Conference, “Cultivating Leadership for a Thriving Future,” taking place online, October 3-4, 2023, and in person October 12-15 in Vancouver, Canada.
  • “University of Phoenix researchers are strong contributors and committed community members at this global conference,” states Hinrich Eylers, Ph.D., P.E., vice provost, College of Doctoral Studies, University of Phoenix.
  • Eylers and Mark Ludorf, Ph.D., Senior Editor, Journal of Leadership Studies, leading an interactive roundtable, “Cultivating Leadership Through Publishing with the Journal of Leadership Studies,” on October 13.
  • Journal of Leadership Studies is a quarterly academic research publication, produced by Wiley, on behalf of the University of Phoenix College of Doctoral Studies.

Buyers Edge Platform Partners with Food Service Direct Offering Unparalleled Convenience and Savings for Foodservice Procurement

Retrieved on: 
Tuesday, September 12, 2023

This partnership will allow foodservice operators to earn cash rebates when they join the Buyers Edge Platform and make eligible purchases through FoodServiceDirect.com.

Key Points: 
  • This partnership will allow foodservice operators to earn cash rebates when they join the Buyers Edge Platform and make eligible purchases through FoodServiceDirect.com.
  • Food Service Direct is the first food-focused online distributor built to provide restaurant operators with access to quality food and supplies in bulk.
  • Buyers Edge Platform partners with hundreds of foodservice suppliers and delivers savings on over 175,000 line items.
  • Operators who purchase from Food Service Direct will now be eligible to earn rebates on those items from Buyers Edge Platform.

RapDev Named Datadog Partner of the Year; Announces Launch of 4 New Products on Datadog Marketplace

Retrieved on: 
Thursday, August 3, 2023

Alongside the recognition, RapDev announced the launch of 4 new offerings on the Datadog marketplace, adding to a portfolio of 30+ products that help Datadog customers extend and enrich observability in their environments.

Key Points: 
  • Alongside the recognition, RapDev announced the launch of 4 new offerings on the Datadog marketplace, adding to a portfolio of 30+ products that help Datadog customers extend and enrich observability in their environments.
  • RapDev was selected as the DPN North America Partner of the Year because of its commitment to driving innovation and excellence in customer outcomes.
  • RapDev and Datadog pursue joint marketing and sale activities, enabling customers to access RapDev's deep engineering expertise gained from installations of more than 100,000 Datadog agents across 100+ Datadog implementations.
  • As part of their continued commitment to expanding the Datadog ecosystem, RapDev is excited to introduce four new offerings on the Datadog Marketplace.

STAGWELL'S (STGW) DONER PARTNERS NETWORK LAUNCHES NEW IN-HOUSE MEDIA STUDIO

Retrieved on: 
Friday, June 30, 2023

DETROIT, June 30, 2023 /PRNewswire/ -- Today, the Doner Partners Network (DPN), part of Stagwell (NASDAQ: STGW), has announced the launch of Doner Media, the network's integrated media offering to deliver clients effective and engaging solutions at the intersection of data and creativity. The DPN, which was recently named to the Ad Age A-List, has appointed Jennifer Villamil as Executive Vice President, Managing Director, to lead the new practice. Villamil brings 18 years of media expertise, most recently serving as Head of Media at The Many. 

Key Points: 
  • Villamil brings 18 years of media expertise, most recently serving as Head of Media at The Many.
  • This next iteration of Doner Media is the integrated media solution more clients are seeking today.
  • With the new Doner Media, The Doner Partners Network now offers clients services across consumer research, strategic planning, creative, production, PR, influencer marketing, diversity marketing and B2B, all from a single engagement and point of contact.
  • Doner Media is the latest addition to the DPN, which acquired Los Angeles-based agency Wolfgang in October 2022.